85 related articles for article (PubMed ID: 26510616)
1. Paving the way to targeting HECT ubiquitin ligases.
Zinzalla G
Future Med Chem; 2015; 7(16):2107-11. PubMed ID: 26510616
[No Abstract] [Full Text] [Related]
2. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases.
Mund T; Lewis MJ; Maslen S; Pelham HR
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16736-41. PubMed ID: 25385595
[TBL] [Abstract][Full Text] [Related]
3. Targeting HECT-type E3 ligases - insights from catalysis, regulation and inhibitors.
Fajner V; Maspero E; Polo S
FEBS Lett; 2017 Sep; 591(17):2636-2647. PubMed ID: 28771691
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Screening of HECT E3 Ubiquitin Ligases Using UbFluor.
Foote PK; Krist DT; Statsyuk AV
Curr Protoc Chem Biol; 2017 Sep; 9(3):174-195. PubMed ID: 28910856
[TBL] [Abstract][Full Text] [Related]
5. An activity-based probe developed by a sequential dehydroalanine formation strategy targets HECT E3 ubiquitin ligases.
Xu L; Fan J; Wang Y; Zhang Z; Fu Y; Li YM; Shi J
Chem Commun (Camb); 2019 Jun; 55(49):7109-7112. PubMed ID: 31157339
[TBL] [Abstract][Full Text] [Related]
6. Development and characterisation of SMURF2-targeting modifiers.
Manikoth Ayyathan D; Levy-Cohen G; Shubely M; Boutros-Suleiman S; Lepechkin-Zilbermintz V; Shokhen M; Albeck A; Gruzman A; Blank M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):401-409. PubMed ID: 33430646
[TBL] [Abstract][Full Text] [Related]
7. Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain.
Wiesner S; Ogunjimi AA; Wang HR; Rotin D; Sicheri F; Wrana JL; Forman-Kay JD
Cell; 2007 Aug; 130(4):651-62. PubMed ID: 17719543
[TBL] [Abstract][Full Text] [Related]
8. Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.
Galdeano C
Future Med Chem; 2017 Mar; 9(4):347-350. PubMed ID: 28263082
[No Abstract] [Full Text] [Related]
9. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy.
Rossi M; Rotblat B; Ansell K; Amelio I; Caraglia M; Misso G; Bernassola F; Cavasotto CN; Knight RA; Ciechanover A; Melino G
Cell Death Dis; 2014 May; 5(5):e1203. PubMed ID: 24787015
[TBL] [Abstract][Full Text] [Related]
10. Tobramycin suppresses HUWE1 degradation to control MCL-1 stability during tumour development.
He J; Wu S; Li X; Tang L; Chen H; Qin L; Xie J; Lu T; Xu W
Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1600-1610. PubMed ID: 32378766
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
Blaquiere N; Villemure E; Staben ST
J Med Chem; 2020 Aug; 63(15):7957-7985. PubMed ID: 32142281
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain.
Ogunjimi AA; Briant DJ; Pece-Barbara N; Le Roy C; Di Guglielmo GM; Kavsak P; Rasmussen RK; Seet BT; Sicheri F; Wrana JL
Mol Cell; 2005 Aug; 19(3):297-308. PubMed ID: 16061177
[TBL] [Abstract][Full Text] [Related]
13. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.
Kuratomi G; Komuro A; Goto K; Shinozaki M; Miyazawa K; Miyazono K; Imamura T
Biochem J; 2005 Mar; 386(Pt 3):461-70. PubMed ID: 15496141
[TBL] [Abstract][Full Text] [Related]
14. Identification of HECT E3 ubiquitin ligase family genes involved in stem cell regulation and regeneration in planarians.
Henderson JM; Nisperos SV; Weeks J; Ghulam M; Marín I; Zayas RM
Dev Biol; 2015 Aug; 404(2):21-34. PubMed ID: 25956527
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional framework for the autoinhibition of Nedd4-family ubiquitin ligases.
Mari S; Ruetalo N; Maspero E; Stoffregen MC; Pasqualato S; Polo S; Wiesner S
Structure; 2014 Nov; 22(11):1639-49. PubMed ID: 25438670
[TBL] [Abstract][Full Text] [Related]
16. A Small Molecule That Switches a Ubiquitin Ligase From a Processive to a Distributive Enzymatic Mechanism.
Kathman SG; Span I; Smith AT; Xu Z; Zhan J; Rosenzweig AC; Statsyuk AV
J Am Chem Soc; 2015 Oct; 137(39):12442-5. PubMed ID: 26371805
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of Nedd4 ubiquitin ligases and their adaptor protein Ndfip1 in a rat model of ischemic stroke.
Lackovic J; Howitt J; Callaway JK; Silke J; Bartlett P; Tan SS
Exp Neurol; 2012 May; 235(1):326-35. PubMed ID: 22417925
[TBL] [Abstract][Full Text] [Related]
18. E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders.
Saravanan KM; Kannan M; Meera P; Bharathkumar N; Anand T
Future Med Chem; 2022 Jan; 14(3):187-201. PubMed ID: 35100004
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
[TBL] [Abstract][Full Text] [Related]
20. Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation.
Mou Y; Wen S; Gao X; Jiang ZY
Future Med Chem; 2022 Jan; 14(3):139-141. PubMed ID: 34814705
[No Abstract] [Full Text] [Related]
[Next] [New Search]
